LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Stock List・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Closed

SectorHealthcare

51.7 -2.49

Buy Sell

Overview

Share price change

24h

Current

Min

51.49

Max

51.82

Key metrics
By Trading Economics
Income	3M -102M
EPS	-1.17
Employees	358
EBITDA	-7.6M -112M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+56.78% upside

Dividends
By Dow Jones
Next Earnings	10 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-384M 5.2B
Previous open	54.19
Previous close	51.7

News Sentiment

By Acuity

50%

139 / 344 Healthcare

Xenon Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Mar 2026, 16:12 UTC

Major Market Movers

Xenon Pharmaceuticals Shares Surge on Positive Study Data for Azetukalner

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

56.78% upside

12 Months Forecast

Average 81.1 USD 56.78%

High 100 USD

Low 63 USD

Based on 17 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Based on 17 analysts giving stock ratings to Xenon Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

139 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.